Gert-jan Ossenkoppele

Gert-jan Ossenkoppele's AcademicInfluence.com Rankings

Philosophy

#7223

World Rank

#10404

Historical Rank

Logic

#4286

World Rank

#5557

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Gert-jan Ossenkoppele's Degrees

Doctorate Medicine University of Amsterdam
PhD Medicine University of Amsterdam

Why Is Gert-jan Ossenkoppele Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gert-jan Ossenkoppele's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. (2017) (3878)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. (2010) (3011)
High-dose daunorubicin in older patients with acute myeloid leukemia. (2009) (754)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. (2007) (747)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. (2018) (689)
A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. (1994) (545)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia (2018) (482)
Prognostic index for adult patients with acute myeloid leukemia in first relapse. (2005) (461)
Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. (2011) (409)
The novel AML stem cell associated antigen CLL-1 aids in discrimination between normal and leukemic stem cells. (2005) (380)
High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. (2013) (378)
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach (2012) (363)
High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. (2003) (361)
High Stem Cell Frequency in Acute Myeloid Leukemia at Diagnosis Predicts High Minimal Residual Disease and Poor Survival (2005) (353)
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. (2014) (282)
High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. (2010) (243)
Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. (2010) (234)
Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. (2022) (218)
Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia (2016) (215)
Cytarabine dose for acute myeloid leukemia. (2011) (215)
Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. A methodological study. (1991) (209)
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. (2008) (206)
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes (2009) (205)
How I treat the older patient with acute myeloid leukemia. (2015) (187)
Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. (2011) (183)
Measurable residual disease testing in acute myeloid leukaemia (2017) (180)
Aberrant marker expression patterns on the CD34+CD38− stem cell compartment in acute myeloid leukemia allows to distinguish the malignant from the normal stem cell compartment both at diagnosis and in remission (2007) (176)
Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. (2007) (174)
MRD parameters using immunophenotypic detection methods are highly reliable in predicting survival in acute myeloid leukaemia (2004) (168)
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. (2011) (167)
Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. (2009) (161)
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. (2020) (158)
Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia (2014) (155)
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. (2005) (151)
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. (2013) (142)
Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. (1997) (140)
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. (2007) (140)
Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. (1997) (137)
C-Type Lectin-Like Molecule-1 (2004) (135)
Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. (2010) (133)
Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2014) (132)
Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. (2002) (132)
Autologous peripheral blood stem cell transplantation for acute myeloid leukemia. (2011) (130)
Comparative analysis of the value of allogeneic hematopoietic stem-cell transplantation in acute myeloid leukemia with monosomal karyotype versus other cytogenetic risk categories. (2012) (129)
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40–60 years (2014) (126)
The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients. (2004) (122)
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms (2011) (118)
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia (2015) (115)
2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. (2021) (112)
P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. (2000) (110)
ALK‐negative systemic anaplastic large cell lymphoma: differential diagnostic and prognostic aspects–a review (2003) (109)
ALK‐negative anaplastic large‐cell lymphoma demonstrates similar poor prognosis to peripheral T‐cell lymphoma, unspecified (2003) (105)
ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination (2000) (104)
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age (2007) (104)
Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. (2014) (104)
Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. (2019) (103)
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients. (2013) (103)
Granzyme B-expressing peripheral T-cell lymphomas: neoplastic equivalents of activated cytotoxic T cells with preference for mucosa-associated lymphoid tissue localization. (1994) (103)
Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. (1996) (102)
Identification of a Small Subpopulation of Candidate Leukemia‐Initiating Cells in the Side Population of Patients with Acute Myeloid Leukemia (2008) (100)
MRD in AML: does it already guide therapy decision-making? (2016) (99)
CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia (2018) (98)
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. (2020) (98)
Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. (2005) (98)
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. (2011) (97)
Prognostic significance of activated cytotoxic T-lymphocytes in primary nodal diffuse large B-cell lymphomas (2004) (95)
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study (2015) (93)
Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. (1995) (92)
Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy (2011) (90)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome. (2008) (90)
The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission (2019) (88)
Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. (2010) (86)
Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. (2013) (85)
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results (2012) (85)
Attenuation of microRNA-126 expression that drives CD34+38- stem/progenitor cells in acute myeloid leukemia leads to tumor eradication. (2014) (84)
Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. (2012) (83)
Autologous stem cell transplantation in elderly patients (≥60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry (2008) (83)
A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia (2016) (80)
Treatment and outcome of 2904 CML patients from the EUTOS population-based registry (2017) (78)
Class II-Associated Invariant Chain Peptide Expression on Myeloid Leukemic Blasts Predicts Poor Clinical Outcome (2004) (75)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party (2021) (75)
Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. (2003) (74)
Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome (2009) (73)
BHRF1, the Epstein-Barr virus (EBV) homologue of the BCL-2 protooncogene, is transcribed in EBV-associated B-cell lymphomas and in reactive lymphocytes. (1995) (73)
Positioning of aminopeptidase inhibitors in next generation cancer therapy (2014) (72)
Intensive postremission chemotherapy without maintenance therapy in adults with acute lymphoblastic leukemia. Dutch Hemato-Oncology Research Group. (1997) (72)
Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (72)
Auto-SCT in refractory celiac disease type II patients unresponsive to cladribine therapy (2011) (71)
Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML. (2017) (71)
Therapy-related myeloid neoplasms in patients with acute promyelocytic leukemia treated with all-trans-retinoic Acid and anthracycline-based chemotherapy. (2010) (71)
Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989–2012 (2016) (70)
Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. (2003) (70)
Granzyme B expression in Reed-Sternberg cells of Hodgkin's disease. (1996) (69)
Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD (2011) (69)
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK). (2012) (68)
Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. (2010) (68)
MOLECULAR CHARACTERIZATION OF MUTANT TP53 ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASTIC SYNDROME. (2022) (68)
Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group (2012) (67)
High percentage of CD34-positive cells in autologous AML peripheral blood stem cell products reflects inadequate in vivo purging and low chemotherapeutic toxicity in a subgroup of patients with poor clinical outcome (2003) (67)
Interleukin-2 receptor alpha-chain (CD25) expression on leukaemic blasts is predictive for outcome and level of residual disease in AML. (2009) (67)
Normal Hematopoietic Stem Cells within the AML Bone Marrow Have a Distinct and Higher ALDH Activity Level than Co-Existing Leukemic Stem Cells (2013) (66)
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia (2018) (65)
Establishing human leukemia xenograft mouse models by implanting human bone marrow-like scaffold-based niches. (2016) (64)
Sequential organ failure predicts mortality of patients with a haematological malignancy needing intensive care (2005) (64)
Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). (2013) (62)
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratio (2016) (61)
A Phase 1/2 Study of SKI-606, a Dual Inhibitor of Src and Abl Kinases, in Adult Patients with Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphocytic Leukemia (ALL) Relapsed, Refractory or Intolerant of Imatinib. (2006) (61)
Adverse effects of activated cytotoxic T lymphocytes on the clinical outcome of nodal anaplastic large cell lymphoma. (1999) (59)
Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? (1998) (59)
Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions (2018) (59)
IN VITRO RESISTANCE TO CYTOSINE ARABINOSIDE, NOT TO DAUNORUBICIN, IS ASSOCIATED WITH THE RISK OF RELAPSE IN DE NOVO ACUTE MYELOID LEUKAEMIA (1996) (56)
A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia (2018) (55)
Acute leukemias of ambiguous lineage: diagnostic consequences of the WHO2008 classification (2010) (55)
A Phase 1 First-in-Human Study of AMG 330, an Anti-CD33 Bispecific T-Cell Engager (BiTE®) Antibody Construct, in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) (2018) (54)
Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera (1992) (53)
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study (2020) (52)
Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML). (2020) (52)
Polymorphisms in the multidrug resistance gene MDR1 (ABCB1) predict for molecular resistance in patients with newly diagnosed chronic myeloid leukemia receiving high-dose imatinib. (2009) (52)
Activated intrinsic apoptosis pathway is a key related prognostic parameter in acute myeloid leukemia. (2007) (52)
Nasal T‐cell lymphoma: a clinicopathological and immunophenotypic analysis of 13 cases (1995) (51)
High numbers of active caspase 3-positive Reed-Sternberg cells in pretreatment biopsy specimens of patients with Hodgkin disease predict favorable clinical outcome. (2002) (51)
Risk factors for relapse after allogeneic transplantation in acute myeloid leukemia (2016) (50)
Interim Analysis of a Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia : The EURO-SKI study (2014) (49)
Expression of the polycomb-group gene BMI1 is related to an unfavourable prognosis in primary nodal DLBCL (2006) (49)
Profiling of apoptosis genes allows for clinical stratification of primary nodal diffuse large B‐cell lymphomas (2007) (49)
Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial (2013) (49)
The value of the MDR 1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia ( AML ) , in relation to MDR 1 status at diagnosis (48)
Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia (2003) (47)
Detection of Epstein–Barr virus nucleic acid sequences and protein in nodal T‐cell lymphomas: relation between latent membrane protein‐1 positivity and clinical course (1993) (47)
The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system (2016) (46)
Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia (2008) (46)
Hypermethylation of the FANCC and FANCL Promoter Regions in Sporadic Acute Leukaemia (2008) (46)
MHC class II molecules in tumour immunology: prognostic marker and target for immune modulation. (2006) (44)
IMGN779, a Novel CD33-Targeting Antibody–Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML (2018) (44)
Outcome of ICU treatment in invasive aspergillosis (1996) (44)
High TRAIL-R3 expression on leukemic blasts is associated with poor outcome and induces apoptosis-resistance which can be overcome by targeting TRAIL-R2. (2011) (42)
A threshold of 10% for myeloperoxidase by flow cytometry is valid to classify acute leukemia of ambiguous and myeloid origin (2013) (42)
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily (2014) (41)
Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). (2006) (41)
CD45RA, a specific marker for leukaemia stem cell sub‐populations in acute myeloid leukaemia (2016) (41)
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes (2017) (41)
Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation (2003) (41)
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. (2007) (40)
Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study (2008) (40)
Absence of leukaemic CD34+ cells in acute myeloid leukaemia is of high prognostic value: a longstanding controversy deciphered (2015) (39)
Leukemia-derived dendritic cells: towards clinical vaccination protocols in acute myeloid leukemia. (2006) (39)
MicroRNA Profiling Can Classify Acute Leukemias of Ambiguous Lineage as Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia (2013) (39)
Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells (2000) (39)
Apoptosis in tumor necrosis factor-alpha-dependent, monocyte-mediated leukemic cell death: a functional, morphologic, and flow-cytometric analysis. (1993) (38)
Nilotinib Is Highly Active and Safe in Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Patients with Imatinib-Resistance or Intolerance. (2007) (37)
Assessment of the normal or leukemic nature of CD34+ cells in acute myeloid leukemia with low percentages of CD34 cells. (2003) (36)
Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes. (2012) (35)
Novel multiparameter flow cytometry assay using Syto16 for the simultaneous detection of early apoptosis and apoptosis‐corrected P‐glycoprotein function in clinical samples (2003) (35)
Leukemia-Specific T-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1BB Targeting (2007) (35)
Multiparameter flow cytometry is instrumental to distinguish myelodysplastic syndromes from non-neoplastic cytopenias. (2016) (34)
Immunologic Purging of Autologous Peripheral Blood Stem Cell Products Based on CD34 and CD133 Expression Can Be Effectively and Safely Applied in Half of the Acute Myeloid Leukemia Patients (2005) (34)
A phase I first‐in‐human study with tefinostat – a monocyte/macrophage targeted histone deacetylase inhibitor – in patients with advanced haematological malignancies (2013) (33)
Gene expression profiling of minimal residual disease in acute myeloid leukaemia by novel multiplex-PCR-based method (2004) (33)
Identification of genes potentially involved in disease transformation of CML (2005) (33)
Improved survival for children and young adolescents with acute myeloid leukemia: a Dutch study on incidence, survival and mortality (2018) (33)
IGFBP7 induces apoptosis of acute myeloid leukemia cells and synergizes with chemotherapy in suppression of leukemia cell survival (2014) (33)
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia (2020) (33)
Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia (2010) (32)
Relation of CD30 expression to survival and morphology in large cell B cell lymphomas. (1994) (32)
MRD in AML: time for redefinition of CR? (2013) (32)
A cytotoxic phenotype does not predict clinical outcome in anaplastic large cell lymphomas. (1999) (32)
Peripheral blood progenitors mobilised by G-CSF (filgrastim) and reinfused as unprocessed autologous whole blood shorten the pancytopenic period following high-dose melphalan in multiple myeloma. (1994) (32)
The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations (2014) (31)
Deletion of the multidrug resistance protein MRP1 gene in acute myeloid leukemia: the impact on MRP activity. (2000) (31)
Reinfusion of unprocessed, granulocyte colony-stimulating factor-stimulated whole blood allows dose escalation of 186Relabeled chimeric monoclonal antibody U36 radioimmunotherapy in a phase I dose escalation study. (2002) (31)
Primary acute myeloid leukemia cells with overexpression of EVI-1 are sensitive to all-trans retinoic acid. (2016) (30)
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. (2019) (30)
Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations (2021) (30)
MRD Tailored Therapy in AML: What We Have Learned So Far (2021) (29)
Chronic myeloid leukemia in the Netherlands: a population‐based study on incidence, treatment, and survival in 3585 patients from 1989 to 2012 (2016) (29)
Feasibility of clinical dendritic cell vaccination in acute myeloid leukemia. (2006) (29)
Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study. (2009) (29)
Antibody response to polysaccharide conjugate vaccines after nonmyeloablative allogeneic stem cell transplantation. (2009) (28)
Apoptotic blebs from leukemic cells as a preferred source of tumor-associated antigen for dendritic cell-based vaccines (2014) (28)
A flow cytometric method to detect apoptosis-related protein expression in minimal residual disease in acute myeloid leukemia* (2003) (28)
Two decades of targeted therapies in acute myeloid leukemia (2021) (27)
A Phase II Study of Nilotinib A Novel Tyrosine Kinase Inhibitor Administered to Imatinib-Resistant or Intolerant Patients with Chronic Myelogenous Leukemia (CML) in Accelerated Phase (AP). (2006) (27)
Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses (2010) (27)
High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes (2014) (27)
Inhibition of the Intrinsic Apoptosis Pathway Downstream of Caspase-9 Activation Causes Chemotherapy Resistance in Diffuse Large B-Cell Lymphoma (2007) (27)
Identification of CD14 as a predictor for leukemic dendritic cell differentiation in acute myeloid leukemia (2003) (26)
Early response monitoring in malignant lymphoma using fluorine-18 fluorodeoxyglucose single-photon emission tomography (1993) (26)
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia. (2000) (26)
Cell Cycle Specific Effects of Tumor Necrosis Factor α in Monocyte Mediated Leukemic Cell Death and the Role of β2-Integrins (1993) (25)
Leukemia-derived dendritic cells in acute myeloid leukemia exhibit potent migratory capacity (2005) (25)
Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results (2008) (25)
Minimal Residual Disease in Acute Myeloid Leukemia Is Predicted by an Apoptosis-Resistant Protein Profile at Diagnosis (2005) (25)
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. (2008) (25)
Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib (2017) (25)
Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. (2014) (24)
Cellular and cytokine dependent monocyte-mediated leukemic cell death: modulation by interferon-gamma and tumor necrosis factor-alpha. (1993) (24)
Recent advances in antigen-loaded dendritic cell-based strategies for treatment of minimal residual disease in acute myeloid leukemia. (2010) (24)
Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR (2015) (24)
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. (2005) (24)
G-CSF (filgrastim)-stimulated whole blood kept unprocessed at 4 degrees C does support a BEAM-like regimen in bad-risk lymphoma. (1996) (24)
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia (2018) (24)
Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. (2017) (24)
Chemotherapeutic treatment of bone marrow stromal cells strongly affects their protective effect on acute myeloid leukemia cell survival (2008) (24)
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes. (2014) (23)
Molecular targeted therapies for diffuse large B‐cell lymphoma based on apoptosis profiles (2010) (23)
TNF-α receptor 1 expression on acute myeloid leukemic blasts predicts differentiation into leukemic dendritic cells (2004) (23)
Value of infliximab (Remicade®) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group (2012) (23)
Noncutaneous T‐cell lymphomas recognition of a lymphoma type (large cell anaplastic) with a relatively favorable prognosis (1993) (23)
Expression of adhesion antigens of human bone marrow megakaryocytes, circulating megakaryocytes and blood platelets (1992) (23)
In vitro drug resistance profile of Philadelphia positive acute lymphoblastic leukemia is heterogeneous and related to age: a report of the Dutch and German Leukemia Study Groups. (2002) (23)
Detection of aberrant transcription of major histocompatibility complex class II antigen presentation genes in chronic lymphocytic leukaemia identifies HLA‐DOA mRNA as a prognostic factor for survival (2009) (23)
Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. (2010) (22)
Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia (2003) (22)
Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells. (2011) (22)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome (2008) (22)
Impact of age on efficacy and toxicity of nilotinib in patients with chronic myeloid leukemia in chronic phase: ENEST1st subanalysis (2015) (22)
Gallium-67 radiotoxicity in human U937 lymphoma cells. (1993) (22)
Human soluble TRAIL/Apo2L induces apoptosis in a subpopulation of chemotherapy refractory nodal diffuse large B‐cell lymphomas, determined by a highly sensitive in vitro apoptosis assay (2006) (21)
Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. (2017) (21)
The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. (1994) (21)
Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia (2012) (21)
MRD in AML: it is time to change the definition of remission. (2014) (20)
The European LeukemiaNet: achievements and perspectives (2011) (20)
RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. (2018) (20)
VLA molecule expression may be involved in the release of acute myeloid leukaemic cells from the bone marrow. (1992) (20)
Can we incorporate MRD assessment into clinical practice in AML? (2019) (20)
Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B‐cell lymphoma (2006) (20)
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia. (2018) (19)
Hypomethylating agents in the treatment of acute myeloid leukemia: A guide to optimal use. (2019) (19)
Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP). (2007) (19)
Monocytic differentiation induction of HL-60 cells by MC 903, a novel vitamin D analogue. (1992) (19)
Chemotherapy in non-Hodgkin's lymphoma during pregnancy. (1991) (19)
Bosutinib is safe and active in patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML) with resistance or intolerance to imatinib and other tyrosine kinase inhibitors (2008) (19)
A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib (2007) (18)
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes (2014) (18)
Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC). (2007) (18)
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (2019) (18)
Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. (2022) (18)
Methylation patterns in CD34 positive chronic myeloid leukemia blast crisis cells (2010) (17)
Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia (2009) (17)
Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia (2018) (17)
Application of flow cytometry for myelodysplastic syndromes: Pitfalls and technical considerations (2016) (17)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. (2021) (17)
Quantification of T‐cell–mediated apoptosis in heterogeneous leukemia populations using four‐color multiparameter flow cytometry (2005) (17)
IGFBP7 Induces Differentiation and Loss of Survival of Human Acute Myeloid Leukemia Stem Cells without Affecting Normal Hematopoiesis. (2018) (17)
Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy (2016) (17)
Long-term follow-up of tandem autologous stem-cell transplantation in multiple myeloma. (2010) (17)
Regulatory T cells and progenitor B cells are independent prognostic predictors in lower risk myelodysplastic syndromes (2015) (16)
Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial (2017) (15)
Purging of peripheral blood stem cell transplants in AML: a predictive model based on minimal residual disease burden. (2005) (15)
Alternative Ii-independent antigen-processing pathway in leukemic blasts involves TAP-dependent peptide loading of HLA class II complexes (2010) (15)
CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial (2020) (15)
Panobinostat and decitabine prior to donor lymphocyte infusion in allogeneic stem cell transplantation. (2020) (14)
The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia (2018) (14)
Monocyte-chemoattractant-protein-1-mediated migration of human monocytes towards blasts from patients with acute myeloid leukemia (2001) (14)
P-095 A five parameter based flow cytometric scoring system refines the revised International Prognostic Scoring System for myelodysplastic syndromes (2013) (14)
Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines* (2020) (14)
Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (2020) (14)
Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission (2013) (14)
Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation (2010) (14)
The EUTOS CML score aims to support clinical decision-making. (2012) (14)
Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization. (2005) (13)
High-dose melphalan with re-infusion of unprocessed, G-CFS-primed whole blood is effective and non-toxic therapy in multiple myeloma (1996) (13)
Targeted therapy of acute myeloid leukemia (2015) (13)
Minimal residual disease cells in AML patients have an apoptosis-sensitive protein profile (2004) (13)
Aberrant Fanconi anaemia protein profiles in acute myeloid leukaemia cells. (2000) (13)
Radiotoxicity of 67-gallium on myeloid leukemic blasts. (1995) (13)
Uncommon lineage switch warrants immunophenotyping even in relapsing leukemia. (2009) (13)
Monitoring of EBV reactivation is justified in patients with aplastic anemia treated with rabbit ATG as a second course of immunosuppression. (2008) (13)
Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. (2021) (12)
High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia. (2014) (12)
Leukaemia cutis: clinical features and treatment strategies. (2002) (12)
The role of BCL-2 and bax protein in monocyte-mediated apoptosis in human leukemic cell lines. (1996) (12)
Challenges in the diagnosis and treatment of secondary acute myeloid leukemia. (2019) (12)
Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant? (2020) (12)
Costs of intensive treatment and follow-up of patients with multiple myeloma. (1998) (11)
Differential capacity of human interleukin-4 and interferon-α monocyte-derived dendritic cells for cross-presentation of free versus cell-associated antigen (2015) (11)
Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells (2006) (11)
Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia. (2007) (11)
Immunophenotyping for diagnosis and prognosis in MDS: ready for general application? (2015) (11)
Promiscuous Binding of Invariant Chain-Derived CLIP Peptide to Distinct HLA-I Molecules Revealed in Leukemic Cells (2012) (11)
Minimal residual disease in acute myeloid leukemia is predicted by P-glycoprotein activity but not by multidrug resistance protein activity at diagnosis (2003) (11)
Phosphotyrosine-based Phosphoproteomics for Target Identification and Drug Response Prediction in AML Cell Lines. (2020) (11)
Six courses of intensified CHOP plus G-CSF compared to eight courses of standard CHOP in patients with intermediate-risk aggressive non-Hodgkin lymphoma (2005) (11)
Genomic amplification of MYC as double minutes in a patient with APL-like leukemia (2014) (11)
Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT) (2016) (10)
Targeting of CLEC12A In Acute Myeloid Leukemia by Antibody-Drug-Conjugates and Bispecific CLL-1×CD3 BiTE Antibody (2010) (10)
Intensive treatment and trial participation in elderly acute myeloid leukemia patients: A population-based analysis in The Netherlands. (2018) (10)
Imatinib use in chronic phase CML in clinical practice: the UNIC study (2008) (10)
Accurate Detection of Residual Leukemic Stem Cells In Remission Bone Marrow Predicts Relapse In Acute Myeloid Leukemia Patients (2010) (10)
Antibody-targeted therapy: a paradigm of innovative treatment strategies in indolent and aggressive B-cell non-Hodgkin lymphoma (2004) (10)
Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG (2015) (10)
A Phase II Study of Oral Panobinostat (LBH589) for Chronic Phase Chronic Myeloid Leukemia (CML) with Resistance to ≥2 BCR-ABL Tyrosine Kinase Inhibitors (2008) (10)
Minimal residual disease in acute myeloid leukemia: already predicting a safe haven? (2010) (10)
Positive selection for CD90 as a purging option in acute myeloid leukemia stem cell transplants (2008) (10)
High Dose Intensive Chemotherapy, as Is Standard in Childhood Leukemia, Is Feasible and Efficacious in Adult Patients with Acute Lymphoblastic Leukemia (ALL) up to the Age of 40 (2009) (10)
Spectrophotometric determination of clonogenic capacity of leukemic cells in a semisolid microtiter culture system. (1993) (9)
Measurable residual disease in acute myeloid leukemia using flow cytometry: approaches for harmonization/standardization (2018) (9)
Leukaemic dendritic cell vaccination for patients with acute myeloid leukaemia (2006) (9)
Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications. (2009) (9)
Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study (2008) (9)
Expression of TNF‐receptor associated factor 2 correlates with poor progression‐free survival time in ABC‐like primary nodal diffuse large B‐cell lymphomas (2008) (9)
Granulocyte colony‐stimulating factor mobilized whole blood containing over 0·3 × 106/kg CD34+ cells is a sufficient graft in autologous transplantation for relapsed non‐Hodgkin's lymphoma (2002) (9)
Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting (2020) (9)
Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System. (2016) (9)
Acute myeloid leukemia in a 23-year-old patient with Beckwith-Wiedemann syndrome. (2002) (9)
Multiparameter flow cytometric quantification of apoptosis-related protein expression (2003) (9)
Targeting the acute myeloid leukemic stem cell compartment by enhancing tumor cell-based vaccines. (2013) (9)
Phase 1 / 2 study to assess the safety , efficacy , and pharmacokinetics of barasertib ( AZD 1152 ) in patients with advanced acute myeloid leukemia (2011) (9)
High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group (2013) (9)
Adhesive capacity of human long-term bone marrow cultures from normals and patients with acute myeloid leukaemia: the influence of adhesion molecules. (1993) (9)
Adult respiratory distress syndrome in Leptospira icterohaemorrhagiae infection (2004) (9)
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia (2022) (8)
Treatment of Multiple Myeloma in Elderly Patients (1997) (8)
Randomized Maintenance Therapy with Azacitidine (Vidaza) in Older Patients (>= 60 years of age) with Acute Myeloid Leukemia (AML) and Refractory Anemia with Excess of Blasts (RAEB, RAEB-t). Results of the HOVON97 Phase III Randomized Multicentre Study (EudraCT 2008-001290-15) (2017) (8)
EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies (2020) (8)
Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells. (2011) (8)
Divergent Autologous T Cell Responses to Leukaemic Dendritic Cells during Remission in Acute Promyelocytic Leukaemia (2005) (8)
Re: Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes. (2019) (8)
Prospective Molecular MRD Detection By NGS: A Powerful Independent Predictor for Relapse and Survival in Adults with Newly Diagnosed AML (2017) (8)
Evaluating ivosidenib for the treatment of acute myeloid leukemia (2020) (8)
A 51‐year‐old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment (2009) (8)
Principles of dendritic cell-based immunotherapy in myeloid leukemia. (2006) (8)
Flowcytometry in myelodysplastic syndromes: towards a new paradigm in diagnosis and prognostication? (2008) (8)
Nilotinib is associated with minimal cross intolerance to imatinib in patients with imatinib-intolerant chronic myelogenous leukemia (CML) in chronic phase (CP) (2007) (7)
Relationship between CD34/CD38 and side population (SP) defined leukemia stem cell compartments in acute myeloid leukemia. (2019) (7)
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS. (2020) (7)
All‐trans retinoic acid toxicity (1992) (7)
The novel bispecific diabody αCD40/αCD28 strengthens leukaemic dendritic cell‐induced T‐cell reactivity (2008) (7)
Minimal residual disease and stem cell transplantation outcomes. (2019) (7)
Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study (2008) (7)
AML and the art of remission maintenance. (2021) (7)
New strategies in hematopoietic stem cell transplantation: G-CSF-mobilized unprocessed whole blood. (1998) (6)
Flt-3 internal tandem duplication hampers differentiation of AML blasts towards leukemic dendritic cells (2006) (6)
The wider perspective: twenty years of clinical trials in myelodysplastic syndromes (2021) (6)
Clinical and Immunological Results Of a Phase I/IIa Study Of Allogeneic Dendritic Cell (DC) Vaccination, An “off The shelf” Treatment To Prevent Or Delay Relapse In Elderly Patients With Acute Myeloid Leukemia (2013) (6)
SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (6)
Specific Depletion of Leukemic Stem Cells: Can MicroRNAs Make the Difference? (2017) (6)
Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter. (2009) (6)
Survival of early posthematopoietic stem cell transplantation relapse of myeloid malignancies (2019) (6)
Imatinib Resistance and/or Intolerance in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study. (2007) (6)
Emerging antibody-targeted therapy in leukemia and lymphoma: current concepts and clinical implications. (2004) (6)
The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood (2014) (6)
Tumor immune escape in acute myeloid leukemia (2012) (6)
Cell cycle specific effects of tumor necrosis factor alpha in monocyte mediated leukemic cell death and the role of beta 2-integrins. (1993) (6)
Induction response criteria in acute myeloid leukaemia: implications of a flow cytometric measurable residual disease negative test in refractory adults (2018) (6)
a study of 319 de novo AML patients High EVI1 expression predicts poor survival in acute myeloid leukemia (2013) (6)
The Novel Oral BET-CBP/p300 Dual Inhibitor NEO2734 Is Highly Effective in Eradicating Acute Myeloid Leukemia Blasts and Stem/Progenitor Cells (2021) (5)
A Five Parameter Based Flow Cytometric Scoring System Refines the Revised International Prognostic Scoring System for Myelodysplastic Syndromes (2012) (5)
Class II-associated invariant chain peptide expression represents a novel parameter for flow cytometric detection of acute promyelocytic leukemia. (2011) (5)
Flow Cytometry in Myelodysplastic Syndromes (2011) (5)
TP53 mutations and relevance of expression of TP53 pathway genes in paediatric acute myeloid leukaemia (2020) (5)
Response to letter commenting on: Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System. (2017) (5)
Methylation of ESR1 and tumour suppressor genes together constitute an independent outcome predictor in acute myeloid leukemia. (2006) (5)
A Multicentre Phase II Study of the Aminopeptidase Inhibitor, CHR- 2797, in the Treatment of Elderly and/or Previously Treated patients with Acute Myeloid Leukemia. (2008) (5)
Maturation-dependent susceptibility to monocyte-mediated cytotoxicity in acute myeloid leukemia. (1994) (5)
In situ loading of skin dendritic cells with apoptotic bleb-derived antigens for the induction of tumor-directed immunity (2014) (5)
Raynaud‐like phenomenon in two patients on nilotinib (2012) (5)
In Acute Myeloid Leukemia Both Malignant and Normal Stem Cells Can Be Detected in Remission Bone Marrow. (2006) (5)
Immunosuppression for Patients with Low and Intermediate Risk Myelodysplastic Syndrome: A Prospective Randomized Multicenter Trial Comparing Antithymocyte Globulin + Cyclosporine with Best Supportive Care: SAKK 33/99. (2007) (5)
© 2012 Landes Bioscience. Do not distribute. Tumor immune escape in acute myeloid leukemia Class II-associated invariant chain peptide expression as result of deficient antigen presentation (2012) (5)
The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved (2010) (5)
Back to basics: in search of the optimal dendritic cell for vaccination in AML. (2008) (5)
Stem cell transplantations in patients with malignant lymphoma: costs in a Dutch university hospital in the period 1984-1995. (1999) (5)
Peripheral blood progenitor cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia (1997) (5)
High-dose melphalan with re-infusion of unprocessed, G-CSF-primed whole blood is effective and non-toxic therapy in multiple myeloma. (1996) (5)
Prediction Of Therapeutic Resistance In Adult Acute Myeloid Leukemia: Analysis Of 4,550 Newly Diagnosed Patients From MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center (2013) (4)
Real-Life Rates of Disease Monitoring in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study. (2007) (4)
Autologous Stem Cell Transplantation in elderly Acute Myeloid Leukemia (2013) (4)
Do peripheral blasts count in myelodysplastic syndromes? (2009) (4)
Flow Cytometric Score Correlates with Clinical Response to Azacitidine In Intermediate-2 and High Risk Myelodysplastic Syndrome Patients (2010) (4)
A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission (2011) (4)
Final analysis of a randomized study on the value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML (2002) (4)
A Phase I Study of CHR-2797, an Orally Active Aminopeptidase Inhibitor in Elderly and/or Treatment Refractory Patients with Acute Myeloid Leukemia or Multiple Myeloma. (2007) (4)
Early assessment of clofarabine effectiveness applying measurable residual disease, including AML stem cells. (2020) (4)
Validation of and proposals for refinements of the WHO 2016 classification for myelodysplastic syndromes (2017) (4)
New approaches for the detection of minimal residual disease in acute myeloid leukemia (2007) (4)
Survival and Prognosis in Patients with First-Line Imatinib Treatment Under Particular Consideration of Death Due to Chronic Myeloid Leukemia (2014) (4)
recommendations from an international expert panel, on behalf of the Diagnosis and management of acute myeloid leukemia in adults: (2010) (4)
PROGNOSTIC IMPACT OF WHITE BLOOD CELL COUNT IN INTERMEDIATE RISK AML (2011) (4)
The adverse prognosis for acute myeloid leukemia patients with superior autologous stem cell mobilization. (2012) (3)
Quantitative Dynamics of Flow Cytometric Aberrancies during Treatment with Erythropoietin/G-CSF Are Predictive for Responses in LOW/INT-I Risk Myelodysplastic Syndromes. (2008) (3)
High rates of molecular response and low incidence of mutations in patients treated with newly diagnosed chronic myeloid leukemia (CML) treated with a dose-escalated combination of imatinib and cytarabin. (2004) (3)
Challenging diagnosis in a patient with clear lymphoid immunohistochemical features and myeloid morphology: mixed phenotype acute leukemia with erythrophagocytosis. (2011) (3)
Differences of cellular composition and adhesion molecule expression in “leukemic” as compared with “normal” human long-term bone marrow cultures (1992) (3)
Allogeneic transplantation after reduced-intensity conditioning with fludarabine–CY for both indolent and aggressive lymphoid malignancies (2014) (3)
Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene (2004) (3)
CML Patients In Clinical Trials Represent Fairly Well The General Population Of CML Patients: A Comparative Analysis Of 5803 Patients From The EUTOS Registry (2013) (3)
AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML (2021) (3)
P-gp and mrp activities in relation to treatment outcome in acute myeloid leukemia. (1999) (3)
Bimodal expression of potential drug target CLL‐1 (CLEC12A) on CD34+ blasts of AML patients (2021) (3)
The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia (2021) (3)
Maturation State-Specific Alternative Splicing in FLT3-ITD and NPM1 Mutated AML (2021) (3)
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment (2022) (3)
Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort (2021) (3)
High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome (vol 93, pg 1894, 2008) (2007) (3)
High Prognostic Impact of Flowcytometric Minimal Residual Disease Detection In Acute Myeloid Leukemia: Prospective Data From the HOVON/SAKK 42a Study (2010) (3)
A randomized study on the value of Fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high risk myelodysplastic syndromes and elderly AML. A report from the Dutch-Belgian hemato-oncology cooperative group (HOVON) (2001) (2)
Application of Kinase Activity Profiles to Predict Upcoming TKI Resistance In CML-Patients. (2010) (2)
Costs of Peripheral Blood Progenitor Cell Transplantation Using Whole Blood Mobilised by Filgrastim as Compared With Autologous Bone Marrow Transplantation in Non-Hodgkin’s Lymphoma (1999) (2)
Procedures for the expansion of CD14(+) precursors from acute myeloid leukemic cells to facilitate dendritic cell-based immunotherapy. (2013) (2)
Validation of a Flow Cytometric Scoring System for the Prognostication of the Myelodysplastic Syndromes: a Retrospective Cohort Study (2010) (2)
Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL): An analysis based on EBMT registry. (2007) (2)
Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS ≥ 1.5) (2008) (2)
Deep Molecular Responses In Patients With Newly Diagnosed Chronic Myeloid Leukemia Receiving Nilotinib As Assessed Within The EUTOS Laboratory Network In The ENEST1st Study (2013) (2)
The EHA Research Roadmap: Malignant Myeloid Diseases (2021) (2)
The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile? (2019) (2)
Statins Potentiate Aminopeptidase Inhibitor (pro)Drug Activity in Acute Myeloid Leukemia Cells (2018) (2)
Standard induction and low dose ara-C treatment in patients over 60 with AML or MDS. (1989) (2)
[Drug treatment of chronic myeloid leukemia: a cost effectiveness analysis of first- and second-line treatment ]. (2003) (2)
In vitro purging of clonogenic leukaemic cells from human bone marrow by interferon-γ-activated monocytes (1994) (2)
Acute lymphoblastic leukaemia in adults: Immunological subtypes and clinical features at presentation (1993) (2)
Specificity of Markers of Leukemia Initiating Cells with a New Multiparameter Flow Cytometry Based Appraoch; Impact for Prognostic and Therapeutic Applications (2010) (2)
P093 Changes in the flowcytometric dysplasia score during treatment with erythropoietin/G-CSF reflect responses in low/int-I risk myelodysplastic syndromes (2007) (2)
Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab (2011) (2)
Allogeneic dendritic cell (DC) vaccination as an “off the shelf” treatment to prevent or delay relapse in elderly acute myeloid leukemia patients: Results of phase I study. (2013) (2)
Assessment of pulmonary microvascular permeability by Gallium-67 in neutropenic patients with adult respiratory distress syndrome (1996) (2)
Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML. (2020) (2)
Role of interferon γ and tumour necrosis factor α in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line (2005) (2)
Trial in Progress: A Phase 3, Randomized, Double-Blind Study of Midostaurin in Combination with Chemotherapy and as Single-Agent Maintenance Therapy in Newly Diagnosed Patients with FLT3 Mutation–Negative Acute Myeloid Leukemia (AML) (2018) (2)
Specific Detection of Aberrant and Normal Stem Cells in Acute Myeloid Leukemia Patients Opens the Way for Defining Highly Specific Targets for Stem Cell Therapy. (2008) (2)
Post-Remission Treatment with Allogeneic Stem Cell Transplantation Improves Outcome in Patients Aged 60 Years and Older with Acute Myeloid Leukemia in First Remission (2014) (2)
Measurable residual disease testing in chronic lymphocytic leukaemia: hype, hope neither or both? (2021) (2)
Targeting histone methylation to reprogram the transcriptional state that drives survival of drug-tolerant myeloid leukemia persisters (2022) (2)
The Roel of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In PATIENTS with POEMS SYNDROME: A Retrospective study of the MM Subcommittee of the Chronic Leukemia Working Party of the EBMT, (2011) (2)
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program (2013) (2)
287 Validation of a flow cytometric scoring system for the prognostication of the myelodysplastic syndromes; A retrospective cohort study (2011) (2)
Escalated dosing schedules of CC-486 for patients experiencing first acute myeloid leukemia (AML) relapse: Results from the phase III QUAZAR AML-001 maintenance trial. (2020) (2)
Monitoring Minimal Residual Disease in ALL and AML (2018) (2)
286 The presence of aberrant myeloid progenitors predicts overall survival in intermediate-2 and high risk myelodysplastic syndromes upon treatment with azacitidine (2011) (2)
Presence of a Flt-3 Internal Tandem Duplication in AML Blasts Predicts Inhibition of Differentiation towards Leukemic Dendritic Cells. (2005) (2)
Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation (2021) (1)
Reduced Expression of CD62L Is Associated with Increased ADAM17 Activity and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) (2014) (1)
Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML (2011) (1)
Short communication Acute myeloid leukemia in a 23-year-old patient with Beckwith- Wiedemann syndrome (2002) (1)
BCL-2 Inhibitor and Conventional Chemotherapy Combinations for Acute Myeloid Leukemia: Shifting From the Unfit to the Fit Patient With AML. (2020) (1)
P037 Apoptotic CD11bdimCD16pos neutrophil subpopulation represents a pitfall in pattern recognition of neutrophil differentiation by flow cytometry in myelodysplastic syndromes (2009) (1)
Tailoring of (immune-)therapy in R-CHOP refractory diffuse large B-cell lymphoma (DLBCL) patients (2008) (1)
Expression of C-Type Lectin-Like Molecule-1 (CLL-1) on Stem Cells Might Discriminate De Novo Acute Myeloid Leukemia from Acute Myeloid Leukemia Originating from Myelodysplastic Syndromes (2008) (1)
Hypermethylation of FANCC and FANCL resulting in a mitomycine-C (MMC) sensitive cellular phenotype in sporadic acute leukemia. (2006) (1)
Intensified CHOP of 12-weeks duration (I-CHOP) plus G-CSF compared with standard CHOP of 24-weeks duration (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin’s Lymphoma. A phase III trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). (2006) (1)
Abstract 2339: IGFBP7 eradicates leukemic stem and progenitor cells in acute myeloid leukemia (2015) (1)
CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies (2010) (1)
Molecular Response with Nilotinib in Patients with Philadelphia Negative (Ph-) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENEST1st Sub-Analysis (2015) (1)
Immunophenotypical Minimal Residual Disease as a Short Term Endpoint for Monitoring Effects of Targeted Inhibitors in Acute Myeloid Leukemia. (2005) (1)
IGFBP7 activates retinoid acid-induced responses in acute myeloid leukemia stem and progenitor cells. (2020) (1)
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome (2022) (1)
Immunophenotypical Sequential MRD Assessment in AML for Prediction of Relapse and Definition of Putative Future Intervention Time Points. (2004) (1)
High CLIP (Class II Associated Invariant Chain Peptide) Expression on Minimal Residual Disease Cells Is Associated with High Relapse Rate in AML Patients. (2006) (1)
C002 C-type lectin-like molecule-1 (CLL-1) and lineage infidelity marker expression as assessed by flow cytometry distinguishes normal and aberrant stem cells in myelodysplastic syndromes (2009) (1)
Profiling of caspase signalling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas (DLBCL) (2005) (1)
High Leukemic Stem Cell Frequency in Remission Bone Marrow Predicts Poor Outcome in Acute Myeloid Leukemia (2008) (1)
Delaying the initiation of dasatinib after imatinib failure has a negative impact on outcome for patients with chronic-phase chronic myeloid leukemia (CP-CML): results from a European observational study (FORTE; CA180-211) (2011) (1)
The predictive value of a positive phase II ASH abstract for peer-reviewed publication and progression to phase III. (2022) (1)
Allogeneic Hematopoietic-Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40-60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning (2011) (1)
EUROPEAN SUB-REGISTRY OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS (PTS) IN FAILURE AFTER IMATINIB THERAPY (IFP): RATIONALE, STUDY DESIGN AND CURRENT STATUS. A STUDY FROM THE EUROPEAN LEUKEMIANET (ELN) (2010) (1)
Characterization of Factors Determining the Kinetics of Disease Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) or Chemotherapeutic Consolidation for Acute Myeloid Leukaemia (AML) in First CR: A Survey from HOVON-SAKK and the Acute Leukaemia Working Party of the EBMT (2016) (1)
Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia (2011) (1)
Patterns of Primary Treatment, Trial Participation and Survival in Adult Acute Myeloid Leukemia: A Nationwide Population-Based Study Among Patients Diagnosed in the Netherlands from 1989 to 2012 (2014) (1)
MicroRNA Expression Profiling of Hematopoietic and Leukemic Stem Cells in Acute Myeloid Leukemia (2011) (1)
P037 Treatment with Epo/G-CSF of patients with low/int-I risk myelodysplastic syndrome diminishes relative CLIP (class II-associated invariant chain peptide) amount on hematopoietic precursor cells (2007) (1)
Identification of Primitive Subpopulations of Acute Myeloid Leukemia Side Population (SP) Stem Cells Defined by Differentiation Status and Malignant Character. (2006) (1)
zacitidine differentially affects CD 4 pos T-cell polarization in vitro and in vivo in igh risk myelodysplastic syndromes (2012) (1)
Safety and Efficacy of Nilotinib Dose Escalation 600mg BID in Patients (pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP). (2007) (1)
[STI571: a new dimension in the treatment of chronic myeloid leukemia]. (2002) (1)
A Human Cell Line Model for Interferon-α Driven Dendritic Cell Differentiation (2015) (1)
TRAIL-R3 Expression on Myeloid Leukemic Blasts Is Related to a Shortened Overall Survival. (2005) (1)
A European observational study of sasatinib in the management of imatinib-resistant and -intolerant patients with chronic myeloid leukemia: FORTE STUDY (CA180-211) (2010) (1)
Reply to Mohty et al (2003) (1)
How I Treat How I treat the older patient with acute myeloid leukemia (2015) (1)
PCHI4: MEDICAL TREATMENT FOR CHRONIC MYELOID LEUKAEMIA (CML):AVERAGE COST EFFECTIVENESS RATIOS OF FIRST AND SECOND LINE TREATMENT (2003) (1)
Outcome and Prognosis of 1955 Patients with Chronic Myeloid Leukemia: First Results of the CML-Registry of the European Treatment and Outcome Study EUTOS. (2009) (1)
Allogeneic SCT planned in CR-1 after intensive chemotherapy in patients with bad prognosis MDS results in better outcome in the intermediate/high-risk cytogenetic group: a study by the EORTC, EBMT, SAKK, HOVON and GIMEMA Leukemia Groups (2006) (1)
A New Flowcytometry-Based Method to Discriminate Malignant From Normal Stem Cells in CML. (2009) (1)
PS1003 HARMONY ALLIANCE: EUROPEAN PUBLIC-PRIVATE DATA COLLECTION LEADS THE WAY - FIRST RESULTS OF THE “PROOF-OF-PRINCIPLE” STUDY IN ACUTE MYELOID LEUKEMIA (2019) (1)
Highly effective mobilization of CD34 positive cells as a poor prognostic factor in acute myeloid leukemia. Possible causes and consequences. (2013) (1)
[The application of hematopoietic growth factors in oncology]. (1991) (1)
Increased TACE (Tumor necrosis factor-alpha±-converting enzyme; ADAM17) Activity Associates with Decreased CD62L Expression, Increased Soluble CD62L Plasma Levels and Predicts Molecular Response to Nilotinib Therapy in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP): Results (2015) (1)
The Role Of High Dose Chemotherapy and Autologous Stem Cell Transplantation (ASCT) In Patients With POEMS Syndrome: A Retrospective study Of The Plasma Cell Disorders Subcommittee Of The Chronic Malignancy Working Party Of The EBMT (2013) (1)
GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION (2017) (1)
Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study (2015) (1)
P086 Flow cytometry in myelodysplastic syndromes: a new tool in the classification and prognostification of low/int-I risk MDS (2007) (1)
High Aldehyde Dehydrogenase Activity (ALDH) Is a General Marker for Normal Hematopoietic Stem Cells but Not Leukemic Stem Cells in Acute Myeloid Leukemia (AML). . (2009) (1)
Acute Myeloid Leukemia Remission Bone Marrow Reveals the Presence of Malignant and Normal Side Population (SP) Stem Cells Whose Frequencies and Ratios Predict Clinical Outcome. (2006) (1)
CC-486 is safe and well-tolerated as maintenance therapy in elderly patients (≥75 years) with acute myeloid leukemia (AML) in first remission following induction chemotherapy: Results from the phase III QUAZAR AML-001 trial. (2020) (1)
Genomic amplification of MYC as double minutes in a patient with APL-like leukemia (2014) (1)
Clinical Cancer Research Collaborative Group (SAKK) and for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON), and Swiss Group for (2011) (1)
90yttrium Ibritumomab Tiuxetan-BEAM Followed by Autologous Stem Cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction Therapy in Patients with High-Risk Aggressive B Cell Non-Hodgkin's Lymphoma (2011) (1)
Harmony Alliance Provides a Machine Learning Researching Tool to Predict the Risk of Relapse after First Remission in AML Patients Treated without Allogeneic Haematopoietic Stem Cell Transplantation (2021) (1)
Acute myeloid leukemia-Section 1 Clinical value of new drugs in acute myeloid leukemia (2019) (0)
15 Identification of prognostic subgroups by flow cytometry in myelodysplastic syndromes (2009) (0)
Reply to J. de la Rubia et al (2011) (0)
Role of signal transduction pathways and the microenvironment in the emergence of minimal residual disease in acute myeloid leukemia (2007) (0)
Biosynthesis and function of base J, a new base in the nuclear DNA of kinetoplastid parasites (1993) (0)
Azacitidine Induces A Shift In Th1/Th17 Ratio and FoxP3 Expression In Anti-CD3 Stimulated CD4+ T-Cells; Implications for the Treatment of Myelodysplastic Syndromes (2010) (0)
The Novel Bispecific Diabody αCD40/αCD28 Strengthens Leukemic Dendritic Cell Induced T Cell Reactivity. (2006) (0)
Various Other 3 q Abnormalities in Acute Myeloid Leukemia (2010) (0)
High expression of decoy receptor TRAIL-R 3 on AML blasts is associated with poor clinical outcome and induces apoptosis resistance which can be overcome by targeting TRAIL-R 2 (2011) (0)
Prognostic Significance of the French-American-British (FAB) Morphologic Subclassification of “Acute Myeloid Leukemia, Not Otherwise Specified” in the 2008 WHO Classification: Analysis of 5,848 Newly Diagnosed Patients From HOVON, MRC/NCRI, SWOG, and MD Anderson Cancer Center (2012) (0)
Leukemia stem cell diversity in CD34-negative versus CD34-positive acute myeloid leukemia. Combining CD34/CD38-defined with SP-defined stem cell populations (2010) (0)
The novel bispecific diabody alpha CD40/alpha CD28 strengthens leukemic dendritic cell induced T cell reactivity. (2006) (0)
Most ASH Abstracts Reporting Phase II Studies Lead to Peer-Reviewed Publications, but Less Than 50% of "Positive" Abstracts Lead to Phase III Investigations: An Analysis of 371 Abstracts 2013 - 2015 (2021) (0)
Modification of Invariant Chain and CLIP Expression Increases the Immunogenicity of Leukemic Blasts to Potentiate Leukemia-Specific T Cell Reactivity (2008) (0)
Abstract LB-246: MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia. (2013) (0)
Comparative Analysis of CD8 + t Cell Priming Efficiencies against a Panel of Leukemia-Associated HLA-A2 Restricted Epitopes Identifies PRAME as a Possible Vaccination Target in AML (2008) (0)
Positive Selection for CD 90 as a Purging Option in Acute Myeloid Leukemia Stem Cell Transplants (2007) (0)
SPECIFIC TARGETING OF ACUTE MYELOID LEUKEMIA STEM CELLS BY INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 (2017) (0)
anaplastic large cell lymphoma Expression levels of apoptosis-related proteins predict clinical outcome in (2013) (0)
Autologous Blood Stem Cell Transplantation Results In Better Relapse-Free Survival Than Consolidation Chemotherapy : Results of a HOVON/SAKK Phase III Trial In 519 AML Patients In First Complete Remission (2010) (0)
Apoptosis profiling in B-cell lymphomas (2004) (0)
TAP- and Proteasome-Dependent Endogenous Antigen Loading of HLA Class II in Leukemic Blasts Introduces a Promising New Target for Generating Leukemia-Specific CD4 + T Cells (2008) (0)
Abstract PO-125: Targeting histone methylation to overrule transcriptionally driven drug resistance in myeloid leukemia (2020) (0)
Midostaurin for FLT3-mutated Acute Myeloid Leukaemia – Considerations for Optimal Use (2019) (0)
hsTRAIL/Apo2L Induces Apoptosis in Enteropathy-Associated T-Cell Lymphoma (2011) (0)
Validation Of a Multi-Diagnostic Approach Including Flow Cytometry To Identify Specific Risk Categories Within Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group (2013) (0)
Can TRAIL overcome resistance to chemotherapy induced apoptosis in diffuse large B cell lymphomas (2003) (0)
Microrna Profiling Classifies Acute Leukemias of Ambiguous Lineage As Either Acute Myeloid Leukemia or Acute Lymphoid Leukemia (2012) (0)
CD38 Expression On CD34+ Cells as a Single Flow Cytometric Parameter to Distinguish Myelodysplastic Syndromes (MDS) From Non-Clonal Cytopenias. (2009) (0)
Allogeneic transplantation after reduced intensity conditioning with fludarabine/cyclophosphamide is feasible and effective for highly resistant indolent and aggressive lymphoid malignancies (2013) (0)
Autologous Stem Cell Transplantation in Refractory Coeliac Disease Type II Patients Unresponsive to Cladribine Therapy (2010) (0)
A Dendritic Cell Based Vaccination Strategy Geared towards Eradication of Leukemic Stem Cells. (2009) (0)
Immune escape mechanism of myeloid leukemic blasts (2007) (0)
P49 The treatment of patients with Myelodysplastic Syndromes in an era of application of new treatment modalities in an outpatient setting requires a multidisciplinary approach (2010) (0)
Protein degradation as a target for anticancer therapy: molecular mechanisms of efficacy and acquired resistance to proteasome and aminopeptidase inhibitors (2016) (0)
[Cell and disease. III. Apoptosis, the biological opposite of mitosis]. (1993) (0)
Midostaurin in Patients (Pts) with Newly Diagnosed FLT3-Mutation Negative Acute Myeloid Leukemia (AML): Final Results and Measurable Residual Disease (MRD) Analyses from the Unify Trial (2021) (0)
Myeloid leukemia role of the bone marrow microenvironment on cell survival in acute myeloid leukemia (2007) (0)
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis (2022) (0)
PB1762 A PHASE III, RANDOMIZED, DOUBLE-BLIND STUDY OF INTENSIVE INDUCTION AND CONSOLIDATION CHEMOTHERAPY PLUS MIDOSTAURIN (PKC412) OR PLACEBO IN NEWLY DIAGNOSED PATIENTS WITH FLT3 MUTATION NEGATIVE AML (2019) (0)
Peripheral blood stem cell transplantation using whole blood derived stem cells (2001) (0)
Flow Cytometry Is Highly Predictive In Excluding Myelodysplastic Syndromes In Patients With Indeterminable Cytopenia: A Prospective Analysis Of 316 Patients (2013) (0)
myeloid leukemia in patients 70 years or older care, including hydroxyurea, in the treatment of newly diagnosed acute A randomized phase 3 study of tipifarnib compared with best supportive (2011) (0)
Implementation of minimal residual disease assessment using multicolour flow cytometry in multicenter clinical studies in acute myeloid leukemia (2006) (0)
Overall Survival and Prognosis in 2190 Patients with First-Line Imatinib Treatment Considering Death Due to Chronic Myeloid Leukaemia as the Only Event (2014) (0)
Functional characterization of minimal residual disease in aml - simultaneous detection of p-glycoprotein function and aberrant phenotypes (2000) (0)
Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial (2022) (0)
CD62L Expression on T Cells is Decreased in Patients with Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) and Predicts Response to Therapy with Frontline Nilotinib (2014) (0)
Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211) (2011) (0)
Impact of Gender on Molecular AML Subclasses - a Harmony Alliance Study (2021) (0)
62 MUTATIONS IN EPIGENETIC REGULATORS ARE SIGNIFICANTLY ASSOCIATED WITH ABERRANT EXPRESSION OF MYELOID DIFFERENTIATION ANTIGENS ON MYELOID PROGENITOR CELLS IN LOW/INTERMEDIATE RISK MDS (2015) (0)
Abstract B21: Dendritic cells loaded with amplified mRNA isolated from leukemic stem-cell-like cells induce specific T-cells (2010) (0)
Optimizing strategies in dendritic cell vaccination in myeloid leukaemia (2006) (0)
Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. (2023) (0)
Role of immune responses focussing on DC in the pathogenesis of low risk and high risk myelodysplastic syndromes: implications for immunotherapy (2013) (0)
Immunogenecity of CML-DC Is Maintained upon Imatinib Mesylate: Implication for Vaccination Regimens. (2004) (0)
Low CLIP Expression On Leukemic Blasts From AML Patients Is Essential for the Generation of Effective CD4 + T Cell Responses. (2009) (0)
S130: NPM1 MUTATED AML: IMPACT OF CO-MUTATIONAL PATTERNS - RESULTS OF THE EUROPEAN HARMONY ALLIANCE (2022) (0)
Application of (RT)-PCR and FISH detection of leukemia associated chromosomal aberrations for research and diagnostic purposes (2001) (0)
disease with aberrant T-cells Autologous hematopoietic stem cell transplantation in refractory celiac (2013) (0)
IL-8 mRNA expression is strongly upregulated during chronic phase CML, independently of cytogenetic reponse (2003) (0)
Aberrant Phenotype of Stem Cells as Assessed by Flow Cytometry Discriminates Between Low and High Risk Myelodysplastic Syndromes and Might Be Instrumental in Predicting Leukemic Evolution. (2009) (0)
Phosphotyrosine‐Based Phosphoproteomics of a Panel AML Cell Lines Reveals Oncogenic Signaling and Hyperactive Tyrosine Kinases as Targets for Treatment: Abstract: AML‐013 (2017) (0)
Treatment with Lenalidomide in Myelodysplastic Syndromes with 5q Deletion; Results From the Patient Named Program (PNP) in the Netherlands (2011) (0)
Value of allogeneic stem cell transplantation (SCT) versus autologous SCT and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial (2010) (0)
Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry (2011) (0)
T Cell Mediated Autologous Cytotoxicity Against Hematopoietic Precursor Cells in Low and Intermediate-1 Risk Myelodysplastic Syndrome. (2007) (0)
Clinical value of new drugs in acute myeloid leukemia (2019) (0)
Clinical radioimmunotherapy with Rhenium-186-labeled monoclonal antibodies (2007) (0)
Clonogenic ability and apoptosis resistance are higher for CD34+ than for CD34− blasts in aml (2000) (0)
XIAP-positive diffuse large B-cell lymphoma cells Small-molecule XIAP antagonist restores caspase-9-mediated apoptosis in (2012) (0)
A STUDY ON THE CLINICAL SIGNIFICANCE OF THE WHO AML SUBTYPE INV(3)(Q21Q26.2)/T(3;3)(Q21;Q26.2) AND VARIOUS OTHER 3Q CHROMOSOMAL ABNORMALITIES IN 6,819 AML CASES (2010) (0)
Autologous stem cell transplantation (ASCT) in patients with POEMS syndrome results in durable symptomatic disease control: A retrospective study of the Plasma Cell Disorder sub-committee of the Chronic Malignancies Working Party of the EBMT (2015) (0)
Empiric Definition of Eligibility Criteria for Clinical Trials in Relapsed/Refractory AML: Analysis of 1,892 Patients from HOVON/SAKK and SWOG (2014) (0)
Cell Cycle Specific Effects of T\imor Necrosis Factor a in Monocyte Mediated Leukemic Cell Death and the Role of /32-Integrins (2006) (0)
Pancreatic pseudocyst in an adult patient after treatment with pegylated asparaginase (2011) (0)
High EVI1 Expression Predicts Outcome in Younger Adult (15 to 60 years) Patients with Acute Myeloid Leukemia and Is Associated with Distinctive Cytogenetic Subgroups (2009) (0)
Measurable Residual Disease Guided Therapy in Intermediate-Risk AML Patients Compared to an Unguided Cohort Using Propensity Score Matching (2022) (0)
Phosphoproteomics for personalized treatment of acute myeloid leukemia with kinase inhibitors (2013) (0)
Bortezomib Induces Caspase-9-Mediated Apoptosis through Activation of the BH3-Only Proteins Noxa, Bik and Puma In Both ALK-Positive and ALK-Negative Anaplastic Large Cell Lymphoma Cells (2010) (0)
The role of BCL-2 and Bax in monocyte mediated apoptosis in human leukemic cell lines (1996) (0)
The European Treatment and Outcome Study (EUTOS) for Chronic Myeloid Leukemia (CML). A Prospective, Population-Based European Registry. (2009) (0)
status at diagnosis previously untreated acute myeloid leukemia (AML), in relation to MDR1 daunorubicin and cytarabine in the treatment of elderly patients with The value of the MDR1 reversal agent PSC-833 in addition to (2013) (0)
Correction to: The Clinical Value of Decitabine Monotherapy in Patients with Acute Myeloid Leukemia (2022) (0)
Overall survival and prognosis in patients with chronic myeloid leukaemia allocated to first-line imatinib treatment - new results from the EUTOS "In-Study" registry (2013) (0)
Leukemic stem cell quantification in newly diagnosed chronic myeloid leukemia patients predicts response to nilotinib therapy (2016) (0)
Differentiation of HL60 cells in coculture with a leukemic stromal layer (1989) (0)
Imbalance in Alternative Splicing of MCL-1 Inhibits Apoptosis in Diffuse Large B-Cell Lymphoma (2014) (0)
Pan-Stakeholder Core Outcome Set (COS) Definition for Selected Hematological Malignancies - Results of the Harmony Alliance (2021) (0)
Detection and eradication of minimal residual disease (MRD) in AML (2007) (0)
Phenotypical and functional characterization of clonogenic acute myeloid leukemia cells in minimal residual disease (2001) (0)
Maturation by Toll Like Receptor Ligand R848 Improves the Uptake of Apoptotic Leukemic Cells by Monocyte Derived Dendritic Cells. (2009) (0)
Functional PRAME Specific T Cells Can Be Cultured From CD8+ Cells From Healthy Donors but Not From Patients at First CR: Implications for Immunotherapeutic Strategies in AML. (2009) (0)
leukemia using histone deacetylase inhibitors Differentiation therapy for the treatment of t(8;21) acute myeloid (2014) (0)
P053 High cytotoxic potential of CD8+/granzymeB+/perforin+ T cells prevents leukemic outgrow of dysplastic hematopoietic precursor cells in patients with low/int-I risk myelodysplastic syndrome (2007) (0)
Leukemia-SpecificT-Cell Reactivity Induced by Leukemic Dendritic Cells Is Augmented by 4-1 BBTargeting (2006) (0)
ExPRESSION DOWN REgUlATION IN THE INTRINSIC APOPTOSIS PATHWAy DURINg FOllOW-UP OF PATIENTS WITH ACUTE MyElOID lEUkEMIA (2011) (0)
Abstract A29: High aldehyde dehydrogenase activity is general marker for normal hematopoietic stem cells but not leukemic stem cells in acute myeloid leukemia (2010) (0)
How to assess minimal residual disease in pediatric and adult acute myeloid leukemia? (2013) (0)
O-16 Different CLIP (class II-associated invariant chain peptide) expression on CD7+ and CD7- hematopoietic precursor cell subpopulations in low-risk MDS (2005) (0)
WHERE SCIENCE MEETS CLINICAL PRACTICE (2014) (0)
Prospective Validation of CD34+CD38- Leukemic Stem Cell Frequency in the HOVON-SAKK 132 Trial: Perspectives for Future Improvements (2022) (0)
Spontaneous apoptosis in CD34+ AND CD34- subpopulations of acute myeloid leukemia patients. (1997) (0)
Profiling of caspase signaling pathways predicts clinical response to chemotherapy in diffuse large B-cell lymphomas (2004) (0)
[Adoptive immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes]. (1989) (0)
Preventie en therapie van tumoren (2002) (0)
Myeloid Leukemic Blasts Use the Endogenous HLA Class I Antigen Processing Machinery for Peptide Loading Onto HLA Class II Molecules: Implications for Immunotherapy. (2009) (0)
Targeted therapy in hematological malignancies: Antibody-targeting, erythropoietin and granulocyte-colony stimulating factor, farnesyl protein transferase and tyrosine kinase inhibitors. (2006) (0)
Survival after Post-Hematopoietic Stem Cell Transplantation AML Relapse: A Single Center Experience (2019) (0)
older age : a randomized phase 2 trial of the Dutch-Belgian Cooperative Addition of bevacizumab to chemotherapy in acute myeloid leukemia (2012) (0)
Aberrant MHC class II antigen presentation is linked to expansion of the activated T cell compartment in B-CLL (2011) (0)
Class-II Associated Invariant Chain Peptide (CLIP) Expression on AML Blasts Adversely Affects Alloreactive CD4+ T Cell Recognition. (2007) (0)
P043 Aberrant immunophenotype of blasts in low and intermediate-1 risk myelodysplastic syndromes predicts response to growth factor treatment. A prospective clinical phase II study (2009) (0)
Scientific Proceedings Second International Symposium on Cytostatic Drug Resistance (1991) (0)
Purging in chronic myeloid leukemia (2001) (0)
Expansion of AML Blasts Induces CD14 Expression and Facilitates Leukemic DC Development for Therapeutic Application In AML (2010) (0)
Monocyte and dendritic cell migration in AML (2001) (0)
Combination of CD34/CD38 Immunophenotypes and Side Population (SP) Reveals the Putative Leukemia Stem Cell/Leukemia Initiating Cell In Acute Myeloid Leukemia. (2010) (0)
European Sub-Registry of Chronic Myelogenous Leukemia (CML) Patients (pts) in Failure after Imatinib Therapy (IFP): Rationale, Study Design and Current Enrollment. (2006) (0)
Assessment of Two Doses of Infliximab in Patients with Low/Intermediate Risk IPSS Myelodysplastic Syndrome (MDS): An EORTC Leukemia Group (LG) Randomized Phase II Trial (06023). (2007) (0)
Treatment and outcome of 2904 CML patients from the EUTOSpopulation-based registry (2017) (0)
Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy (2013) (0)
Does RAD21 Co-Mutation Have a Role in DNMT3A Mutated AML? Results of Harmony Alliance AML Database (2021) (0)
Measurable Residual Disease (MRD): Is it a Thing in AML?: TH‐S19‐AML‐040 (2018) (0)
Immunomodulatory Effects of Azacitidine Treatment In High Risk Myelodysplastic Syndrome (2010) (0)
Identification of targeted therapies for anaplastic large cell lymphoma based on apoptosis expression profiles (2010) (0)
Immune Monitoring In Patients With Early Chronic Phase Chronic Myelogenous Leukemia (CML-CP) Treated With Frontline Nilotinib (2013) (0)
Erythroid Lineage Analysis By Flow Cytometry Is of Highly Additive Value for MDS Diagnosis: A Study on Behalf of the HOVON89 Study Group (2014) (0)
Apoptosis profiling in diffuse large B-cell lymphomas for tailoring of therapy. (2006) (0)
The added value of multi‐state modelling in a randomized controlled trial: The HOVON 102 study re‐analyzed (2021) (0)
Detection of minimal residual disease in patients treated with high dose melphalan (HDM)/interferon-alpha (INF-a) included in a low-grade B-NHL protocol (2001) (0)
Abstract LB-45: High aldehyde dehydrogenase activity is a marker for normal hematopoietic stem cells but not leukemic stem cells in acute myeloid leukemia: novel therapeutic implications. (2011) (0)
Autologous stem cell transplantation (ASCT) for elderly patients (>= 60 years) with non-hodgkin's lymphoma (NHL) (2007) (0)
P-078 Flow cytometry has a high negative predictive value for excluding MDS in patients with cytopenia and indeterminate cytomorphology and cytogenetics (2013) (0)
In human macrophages the development of the endogenous peroxidatic activity pattern coincides with the expression of the differentiation antigen RFD7: An ultrastructural immunocytochemical study (1989) (0)
The nature of primitive clonogenic AML cells and the role in emergence of minimal residual disease in AML (2005) (0)
Prevention and therapy of tumors (2002) (0)
Mutant NPM1 MRD and FLT3-ITD Status are Independent Prognostic Factors for the Risk of Relapse in AML Patients (2016) (0)
Treatment of Newly Diagnosed AML in Fit Patients (2021) (0)
Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome (2005) (0)
Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival. (2023) (0)
High Expression of Decoy Receptor TRAIL-R3 on AML Blasts Is Associated to Shortened Overall Survival. TRAIL-R3 Induced Apoptosis Resistance Can Be Overcome by Specifically Targeting TRAIL-R2 in Vitro (2008) (0)
Multicolour Flow Cytometric Finetuning of the Classification of Myelodysplastic Syndromes. (2006) (0)
New insights in mechanims involved in apoptosis resistance in acute myeloid leukemia (2005) (0)
Chapter 4 SPECIFIC ERADICATION OF LEUKEMIC STEM CELLS : CAN MICRORNAS MAKE THE DIFFERENCE ? (2016) (0)
Detection of aberrant transcription of MHC class II antigen presentation genes in chronic lymphocytic leukemia identifies HLA-DOA mRNA as a prognostic factor for survival (2009) (0)
De rol van flowcytometrie in de classificatie van het myelodysplastisch syndroom (2009) (0)
Is hsp70 another target for Ph+ leukemias? (2004) (0)
Outcome of Nodal Anaplastic Large Cell Lymphoma Adverse Effects of Activated Cytotoxic T Lymphocytes on the Clinical (2011) (0)
LMP1 and LMP2 specific T-cell stimulation and immunotherapy in EBV+ Hodgkin's disease (2001) (0)
Identification Of Chromosomal Abnormalities By Microarray-Based Genomic Profiling As Compared To Karyotyping In Patients With Low and Intermediate-1 Risk Myelodysplastic Syndromes Within a Prospective Clinical Trial: A Study On Behalf Of The HOVON89 Study Group (2013) (0)
Decreased Expression of CD62L and CD54 Correlates with Poor Cytogenetic Risk Group In Myelodysplastic Syndromes (2010) (0)
Abstract 3890: MicroRNA-551b is highly expressed in hematopoietic stem cells and expression in acute myeloid leukemia is associated with relapse and poor survival (2014) (0)
Title : Establishing a human leukemia xenograft mouse model (2016) (0)
Targeting miRNA-551b, a "Stemness"-like microRNA, to Eradicate AML (Stem) Cells (2018) (0)
The role of bcl-2 and p53 in lineage specific monocyte mediated leukemic cell death (2001) (0)
Microrna-551b Is Preferentially Expressed In Hematopoietic Stem and Multipotent Progenitor Cells and High Expression In Acute Myeloid Leukemia Is An Independent Prognostic Factor For Relapse and Poor Survival (2013) (0)
prospective sibling donor versus no-donor comparison adult patients with acute lymphoblastic leukemia in first remission: a Myeloablative allogeneic versus autologous stem cell transplantation in (2013) (0)
P038 Decreased expression of CD62L, CD54 and CXCR4 in CD34pos cells adds to the pro-apoptotic profile in low risk and myelodysplastic syndromes (2009) (0)
Role of interferon gamma and tumour necrosis factor alpha in monocyte-mediated cytostasis and cytotoxicity against a human histiocytic lymphoma cell line. (1992) (0)
Abstract 1820: Phosphoproteomics of a panel of AML cell lines reveals oncogenic signaling and candidate drivers (2015) (0)
Author Correction: SF3B1 as therapeutic target in FLT3/ITD positive acute myeloid leukemia (2021) (0)
Abstract 1114: IGFBP7 reduces acute myeloid leukemia stem cell survival without affecting normal hematopoiesis (2018) (0)
Apoptotic Blebs From Leukemic Cells as a Source of Tumor Associated Antigen for Monocyte-Derived Dendritic Cell Loading (2010) (0)
S2024 Refractory Celiac Disease Type 2: Haematopoietic Autologous Stem Cell Transplantation Does Improve Clinical Outcome (2010) (0)
Aberrant Phenotype of blasts in Low and Intermediate-1 Risk Myelodysplastic syndromes Predicts Response of Growth Factor Treatment. a Prospective clinical Phase-II Study. (2008) (0)
Insulin-like Growth Factor Binding Protein 7 Activates the Retinoid Acid Differentiation Pathway in Acute Myeloid Leukemia Cells (2018) (0)
Overall Survival and Prognosis In Patients With First-Line Imatinib Treatment Under Consideration Of Death Due To Any Cause and Death Due To Chronic Myeloid Leukemia Only (2013) (0)
Identification of a Small Subpopulation of Candidate Leukemia Initiating Cells within the Side Population (SP) of Patients with Acute Myeloid Leukemia. (2007) (0)
The Comparative Value of Hematopoietic Stem Cell Transplantation and Chemotherapy in Cytogenetically Normal AML Subclassified By NPM1 Mutation Status and FLT3-ITD Allelic Ratio (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gert-jan Ossenkoppele?

Gert-jan Ossenkoppele is affiliated with the following schools: